Member Info for Stockkid

I was fortunate enough to take a sizeable position here the other week at around 0.016, been averaging up on some of these dips. Although this has been more manipulated than Mrs Wolf, what we have here is an absolute game changer! Even if Thar etc went nowhere, that 20% Free carry is Insane!! it's been a while since I've come across a potential like this on Aim! I'm holding firm, first slice will be around 1-1.2p

This will tank below placing today

It's starting to make sense as to why on earth there has been no Placing RNS, this to me screams an alternative route to funding, commercial loan maybe!?

FFS, give it a rest the pair of you, just filter each other and be done, lets get back to proper discussions/ research

We won't see much movement until the resolution, Monday I think?

Elucidare is a boutique technology development and investment advisory business. Our activities span the entire innovation and investment cycle from invention to trade sale or IPO.

I can't see anyone wanting to bid for this, without FDA, and the horrendous cash burn! jut wait and pick up the IP for nowt!?

King Charles maybe that embarrased for Genedrive and its performance he thinks well I better step in!

We'll be doing an 'Atlas Metals' soon enough!!

This is simply a High Risk High reward play, the rewards could be absolutly Insane!!! Like 10 x! But this is the Aim game, it could get the other way, From my point of view it's definitely worth the Large punt! it's all about that roll of the dice, be nice to get back to sensible discussion on potential outcomes, rather than you said this, your ramping that, try get back to some sensible outcomes with research, anyone?

Unfortunately even with NHSE guidance, they will still dilute, they don't care about shareholders, they never have done, none of them have any decent skin in the game, they will wait for the announcement, the stock rises 2-3p and then announce a dilution! Pains me but this is what will happen!

This will absolutely end get getting a buyout in the next year or two, and were talking £20+ easy

Interesting a Director at Bristol Myers squibb and Glaxo have liked the post!

🔸 1. Conservative Case – Modest NHS Uptake

Valuation: £50 million (reflects early revenues & NICE credibility)

Per Share: ~9.2p

🔸 2. Base Case – Widespread NHS Adoption + PCI rollout

NHS-wide implementation + ACS adoption in secondary care.

Annual revenues could hit £5–10 million within 2–3 years.

Valuation: £100–150 million (10–15× forward sales)

Per Share:

£100m = ~18.4p

£150m = ~27.6p

🔸 3. Strategic Acquisition Case – Global expansion (EU, US, multi-product)

CYP2C19 + MT-RNR1 bundled pharmacogenetic platform.

Expansion to U.S. (FDA clearance) and private sector deals.

Valuation: £200–300 million

Per Share:

£200m = ~36.8p

£300m = ~55.2p

Realistic Target Based on Current Data

Given:

NICE endorsement

Cost-effectiveness validation (saves NHS £160m/year)

First revenues flowing in

Market cap just £7.74m

A realistic buyout target on successful CYP2C19 implementation across the NHS (base case) would be £100–150 million, translating to a takeout price of ~18–28p/share — a 10–20x premium to the current price. Higher strategic value could push it toward 30–50p+, but that would require global commercial traction.

Ahh Thanks Franky, love you too x

Ohhhh Lionel, you break our hearts X

Not according to AI, using all the latest data!

Why should we be excited and ignore the doomsayers.... This should cause a stir :-)

The average stock forecast for Genedrive PLC (GDR.L) in the next 12 months is 86.7 GBP. This price target corresponds to an upside of 4524%. The range of stock forecasts for GDR.L is 85.85 - 89.25 GBP. Based on the ratings of 9 analysts, the consensus recommendation for GDR.L is BuyScottish Government Investment: On March 17, 2025, it was announced that the Scottish government will invest £800,000 to implement Genedrive's MT-RNR1-ID and CYP2C19-ID kits into NHS Scotland. This phased national rollout, starting in October, aims to test over 3,000 newborns annually once fully implemented. ​

Clinical Adoption: Genedrive's CYP2C19-ID kit has been adopted for routine clinical use in the hyperacute and acute stroke units of Peterborough City Hospital. This integration signifies growing acceptance of Genedrive's technology in clinical settings. ​

NICE Recommendation: In July 2024, the UK's National Institute for Health and Care Excellence (NICE) recommended the Genedrive® CYP2C19-ID test as the point-of-care test of choice before clopidogrel administration in managing ischemic stroke and transient ischemic attack patients. ​

FDA Breakthrough Device Designation: In July 2024, Genedrive received Breakthrough Device Designation from the U.S. Food and Drug Administration for its MT-RNR1 ID Kit, potentially expediting its regulatory review and market entry in the U.S. ​

Positive Outlook: Some analysts predict a 12-month price target of 86.70 pence, suggesting a potential upside of over 4,000%. ​

I think we'll easily see 5-8p on sales news from UAE, and when USA hits..... anything is possible! more likely buyout offer before we get to 12p+

Lets say we get the FDA all clear, what is that likely to look like share price wise, I know it's anyones guess, but any ideas? and would we be likely to have a buyout soon after? Just Interested in others opinions